Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-NDTranslational lung cancer research

Should we wait?-timing of SRS in EGFR-mutant NSCLC.

  • Michael T Milano1
  • Amit K Chowdhry1,2
  • Nicholas J Denunzio1
  • Kenneth Y Usuki1
  1. 1Department of Radiation Oncology, University of Rochester, Rochester, NY, USA.
  2. 2Department of Radiation Oncology, AdventHealth Cancer Institute, Orlando, FL, USA.
Read full textPDFDOICite

Related

  1. Treatment sequences in EGFR mutant advanced NSCLC
    Wespiser Mylène, A. Swalduz, M. Pérol
    Lung CancerPeer-reviewedLicence not statedFull text16 citedOncologyHAL
  2. Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
    Xinwei Wu, Danni Wang, Yangbin Shi +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  3. High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
    Yoshihiko Sakata, Kenta Murotani, Daichi Fujimoto +18
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Mechanism-Matched Pharmacology of Resistance in EGFR-Mutant NSCLC: Genomic Bypass, Lineage Plasticity, Antibody-Drug Conjugates, and Candidate Biophysical Targets
    Yohan Seo
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
  5. Live-cell FRET imaging-based efficacy prediction of EGFR-TKIs in EGFR L858R-mutant NSCLC.
    Xin Li, Lingao Dai, Pingshan Yang +7
    Clinical and translational medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{milano2026should,
  title = {{Should we wait?-timing of SRS in EGFR-mutant NSCLC.}},
  author = {Michael T Milano and Amit K Chowdhry and Nicholas J Denunzio and Kenneth Y Usuki},
  journal = {Translational lung cancer research},
  year = {2026},
  month = oct,
  doi = {10.21037/tlcr-2026-1053},
  url = {https://europepmc.org/article/MED/42999604},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Should we wait?-timing of SRS in EGFR-mutant NSCLC.
AU  - Michael T Milano
AU  - Amit K Chowdhry
AU  - Nicholas J Denunzio
AU  - Kenneth Y Usuki
PY  - 2026
DA  - 2026/10/19
JO  - Translational lung cancer research
DO  - 10.21037/tlcr-2026-1053
UR  - https://europepmc.org/article/MED/42999604
SN  - 2218-6751
SN  - 2226-4477
ER  -